Tarsus Pharmaceuticals (TARS) Intangibles (2023 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Intangibles of $7.1 million for Q1 2026, down 11.87% year-over-year from $8.1 million in Q1 2025, and down 3.26% quarter-over-quarter from $7.4 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Intangibles (2023 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Intangibles history runs 4 years deep, the most recent figure standing at $7.1 million for Q1 2026.
- In Q1 2026, Intangibles fell 11.87% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 11.87% YoY), while the FY2025 annual figure was $7.4 million, down 11.53% from the prior year.
- Intangibles for Q1 2026 stood at $7.1 million, down from $7.4 million in the prior quarter.
- The five-year high for Intangibles was $8.6 million in Q3 2024, with the low at $3.7 million in Q2 2024.
- The 4-year median for Intangibles is $7.4 million (2025), against an average of $6.4 million.
- The sharpest annual moves came in 2024 and 2026: Intangibles surged 115.96% in 2024, then declined 11.87% in 2026.
- Tarsus Pharmaceuticals' Intangibles stood at $3.9 million in 2023, then surged by 115.31% to $8.3 million in 2024, then decreased by 11.53% to $7.4 million in 2025, then fell by 3.26% to $7.1 million in 2026.
- Business Quant data shows TARS's Intangibles at $7.1 million in Q1 2026, $7.4 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.89 Mn |
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 7.37 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 7.85 Mn |
| Mar 31, 2025 | 8.09 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 8.57 Mn |
| Jun 30, 2024 | 3.67 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Dec 31, 2023 | 3.87 Mn |
| Sep 30, 2023 | 3.97 Mn |